CPC A61K 38/2242 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 38/1709 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01)] | 16 Claims |
1. A method of treating hypochondroplasia in a subject in need thereof comprising the step of administering to said subject a composition comprising a C-type natriuretic peptide (CNP) variant in an amount of at least 7.5 μg/kg of said CNP variant peptide, wherein the CNP variant is selected from the group consisting of:
QEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC (SEQ ID NO: 1);
MQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 2);
PQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 3);
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSNSGLGC (SEQ ID NO: 4);
PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 5);
MGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 6); and
GQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (SEQ ID NO: 7), wherein the CNP variant is in a formulation comprising citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, D-mannitol, L-methionine and polysorbate 80 and wherein the step of administering treats said hypochondroplasia.
|